Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 7:22 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Glomerular Filtration Rate Clear all
Completed Phase 2 Interventional Results available

Evaluation of Coffee Therapy for Improvement of Renal Oxygenation

NCT03878277
View directory record Official record
Conditions
Type1diabetes, Type1 Diabetes Mellitus, Diabetic Kidney Disease, Juvenile Diabetes, Diabetic Nephropathies, Diabetes Complications, Diabetes, Autoimmune
Interventions
Starbucks® Cold brew - 325ml bottle
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
12 Years to 21 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 14, 2022 · Synced Sep 28, 2026, 7:22 AM EDT
Completed Not applicable Interventional Results available

Oral Paricalcitol in Kidney Transplant Recipients

NCT00587158
View directory record Official record
Conditions
Transplant; Failure, Kidney, Renal Disease, End Stage, Hyperparathyroidism, Secondary
Interventions
Paricalcitol, Corticosteroid Avoidance Immune Suppression Protocol
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
2
States / cities
Scottsdale, Arizona • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 12, 2013 · Synced Sep 28, 2026, 7:22 AM EDT
Completed Phase 1 Interventional

A Study to Evaluate the Safety and Tolerability of ABT-614 and Its Effect on Kidney Function in Subjects With Type 2 Diabetes and Chronic Kidney Disease With Protein in Their Urine.

NCT01464320
View directory record Official record
Conditions
Type 2 Diabetics, Chronic Kidney Disease, Protein in Urine
Interventions
ABT-614, Placebo Comparator
Drug
Lead sponsor
Abbott
Industry
Eligibility
19 Years to 70 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 21, 2012 · Synced Sep 28, 2026, 7:22 AM EDT
Completed No phase listed Observational

Study to Develop a Tool to Estimate the Kidney Function in Databases Without Laboratory Data

NCT03605810
View directory record Official record
Conditions
Renal Function
Interventions
No Intervention
Other
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
5,132,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Whippany, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 9, 2019 · Synced Sep 28, 2026, 7:22 AM EDT
Completed Phase 2 Interventional Results available

Zibotentan and Dapagliflozin for the Treatment of CKD (ZENITH-CKD Trial)

NCT04724837
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Zibotentan, Dapagliflozin, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
542 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
50
States / cities
Huntsville, Alabama • Beverly Hills, California • Downey, California + 44 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2024 · Synced Sep 28, 2026, 7:22 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics of MP-3180 in Healthy Volunteers

NCT02098174
View directory record Official record
Conditions
Glomerular Filtration Rate, Acute Kidney Injury
Interventions
MP-3180, Iohexol comparator
Drug · Other
Lead sponsor
MediBeacon
Industry
Eligibility
22 Years and older
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 22, 2016 · Synced Sep 28, 2026, 7:22 AM EDT
Completed Phase 3 Interventional Results available

Study of the Safety and Efficacy of PRX-102 Compared to Agalsidase Beta on Renal Function

NCT02795676
View directory record Official record
Conditions
Fabry Disease
Interventions
PRX-102 (pegunigalsidase alfa), agalsidase beta
Biological
Lead sponsor
Protalix
Industry
Eligibility
18 Years to 60 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
15
States / cities
Birmingham, Alabama • Phoenix, Arizona • Orange, California + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 12, 2023 · Synced Sep 28, 2026, 7:22 AM EDT
Completed Not applicable Interventional Results available

Study of Protective Effects of Paricalcitol on Inner Layer of Vessels and Its Protective Effect on Inflammation

NCT00428246
View directory record Official record
Conditions
Chronic Kidney Disease, Endothelial Dysfunction, Inflammation, Hypertension
Interventions
paricalcitol, Placebo
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jun 2, 2009 · Synced Sep 28, 2026, 7:22 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study of MB-102 (Relmapirazin) and the Use of the MediBeacon® Transdermal GFR Measurement System Using the TGFR Reusable Sensor With Disposable Adhesive Ring

NCT05777174
View directory record Official record
Conditions
Kidney Diseases, Kidney Injury, Kidney Failure
Interventions
MB-102, MediBeacon Transdermal Glomerular Filtration Rate Measurement System (TGFR)
Drug · Device
Lead sponsor
MediBeacon
Industry
Eligibility
18 Years and older
Enrollment
149 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
5
States / cities
Chicago, Illinois • Columbus, Ohio • Austin, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2025 · Synced Sep 28, 2026, 7:22 AM EDT
Completed Phase 1 Interventional Results available

A Study To Evaluate The Effect Of CP-690,550 On Measures Of Kidney Function In Patients With Active Rheumatoid Arthritis

NCT01484561
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
CP-690,550 or Placebo, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
5
States / cities
South Miami, Florida • Albany, New York • Duncansville, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2014 · Synced Sep 28, 2026, 7:22 AM EDT
Terminated Phase 2 Interventional Results available

A Study to Examine Past Estimated Glomerular Filtration Rate (eGFR) Slope as a Risk Marker for Rapid Kidney Function Decline in People With Chronic Kidney Disease

NCT04881448
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
collection of serum/capillary creatinine values
Diagnostic Test
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
223 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
19
States / cities
Huntsville, Alabama • Victorville, California • Bloomfield, Connecticut + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2023 · Synced Sep 28, 2026, 7:22 AM EDT
Terminated Phase 4 Interventional Results available

A Clinical Trial of Oral Versus IV Iron in Patients With Chronic Kidney Disease

NCT00830037
View directory record Official record
Conditions
Chronic Kidney Disease, Iron-deficiency Anemia
Interventions
IV Iron, Ferrous Sulfate
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jul 20, 2016 · Synced Sep 28, 2026, 7:22 AM EDT
Completed Phase 2 Interventional Results available

Tetrahydrobiopterin in Patients With Chronic Kidney Disease (CKD) and Albuminuria

NCT00625820
View directory record Official record
Conditions
Kidney Disease, Albuminuria
Interventions
6R BH4, Vitamin C
Drug · Dietary Supplement
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 75 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 17, 2016 · Synced Sep 28, 2026, 7:22 AM EDT
Completed No phase listed Observational

Evaluation of New Test Method to Measure Kidney Function

NCT00026715
View directory record Official record
Conditions
Kidney Disease
Interventions
Not listed
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
Not listed
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 28, 2026, 7:22 AM EDT
Withdrawn Phase 3 Interventional

Atacicept in Subjects With Active Lupus Nephritis (COMPASS)

NCT05609812
View directory record Official record
Conditions
Lupus Nephritis (LN)
Interventions
Atacicept, Placebo
Drug
Lead sponsor
Vera Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
26
States / cities
Huntsville, Alabama • La Jolla, California • La Palma, California + 19 more
Source: ClinicalTrials.gov public record
Updated May 22, 2025 · Synced Sep 28, 2026, 7:22 AM EDT
Completed Phase 3 Interventional Results available

Open Label Extension Study of 1 mg/kg Pegunigalsidase Alfa Every 2 Weeks in Patients With Fabry Disease

NCT03566017
View directory record Official record
Conditions
Fabry Disease
Interventions
pegunigalsidase alfa
Drug
Lead sponsor
Chiesi Farmaceutici S.p.A.
Industry
Eligibility
18 Years to 60 Years
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
15
States / cities
Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Sep 28, 2026, 7:22 AM EDT
Completed Phase 4 Interventional Results available

Rituximab in Progressive Immunoglobulin A (IgA) Nephropathy

NCT00498368
View directory record Official record
Conditions
IgA Nephropathy
Interventions
Intravenous Rituximab, ACE/ARB, Omega-3 Fatty Acid Fish Oil Supplement
Drug · Dietary Supplement
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 70 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
5
States / cities
San Francisco, California • Rochester, Minnesota • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2017 · Synced Sep 28, 2026, 7:22 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Bariatric Surgery and the Kidney

NCT01410994
View directory record Official record
Conditions
Proteinuria
Interventions
Not listed
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 27, 2015 · Synced Sep 28, 2026, 7:22 AM EDT
Completed Phase 2 Interventional Results available

Safety Study of GE-145 320 mg I/mL Injection vs. Iopamidol 370 mg I/mL in Elderly Subjects Undergoing Coronary Procedure

NCT01252810
View directory record Official record
Conditions
Chronic Renal Insufficiency, Diabete Mellitus, Congestive Heart Failure
Interventions
GE-145
Drug
Lead sponsor
GE Healthcare
Industry
Eligibility
65 Years and older
Enrollment
284 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 28, 2018 · Synced Sep 28, 2026, 7:22 AM EDT
Not listed Phase 4 Interventional

Impact of Conversion From Tacrolimus to Sirolimus in African American Renal Transplant Recipients

NCT00999258
View directory record Official record
Conditions
Glomerular Filtration Rate, Chronic Allograft Nephropathy
Interventions
sirolimus
Drug
Lead sponsor
Temple University
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 20, 2009 · Synced Sep 28, 2026, 7:22 AM EDT
Completed No phase listed Observational

Impact of Drug Therapy and Co-Morbidities on the Development of Renal Impairment in HIV-Infected Patients

NCT00551655
View directory record Official record
Conditions
Human Immunodeficiency Viruses, Kidney Failure, HIV Infections
Interventions
Not listed
Lead sponsor
AIDS Arms Inc.
Other
Eligibility
18 Years and older
Enrollment
684 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 5, 2007 · Synced Sep 28, 2026, 7:22 AM EDT
Completed No phase listed Observational

Comparison of Creatinine Clearance Calculation for Estimation of GFR in Patients Receiving HD Methotrexate

NCT01319591
View directory record Official record
Conditions
CNS Lymphoma, CNS Involvement of Systemic Lymphoma
Interventions
Not listed
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 21, 2019 · Synced Sep 28, 2026, 7:22 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Pharmacokinetic Study of YM178 in Normal Subjects and Those With Mild, Moderate, and Severe Renal Impairment

NCT00750620
View directory record Official record
Conditions
Renal Impairment
Interventions
YM178
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years to 79 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
2
States / cities
Anaheim, California • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Sep 4, 2013 · Synced Sep 28, 2026, 7:22 AM EDT
Completed Not applicable Interventional

Effect of Low Frequency Ultrasound on Kidney Function

NCT02026544
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Low Frequency Therapeutic Ultrasound
Device
Lead sponsor
Sonogenix
Industry
Eligibility
18 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 21, 2021 · Synced Sep 28, 2026, 7:22 AM EDT